Parsortix Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • 2ndary - Private

Parsortix General Information

Description

Developer of particle separation technology to serve a range of potential applications in medical devices and diagnostics. The company's technology comprises a separation device that enables particles suspended in a fluid to be captured with a high degree of selectivity, allowing the fluid medium itself and other suspended particles to pass through the device, thereby helping in the determination of chromosomal abnormalities in the first trimester of pregnancy without the need for invasive diagnostic procedures and for applications in bone marrow transplant procedures used in the therapeutic regimen for cancer treatment.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Parent Company
Corporate Office
  • 3711 Market Street
  • University City Science Center 8th Floor
  • Philadelphia, PA 19104
  • United States
+1 (215) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Parsortix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 05-Nov-2018 Completed Generating Revenue
4. Angel (individual) 06-Aug-2012 Completed Generating Revenue
3. Merger/Acquisition 05-Oct-2011 Completed Generating Revenue
2. Accelerator/Incubator 10-Jun-2011 Completed Generating Revenue
1. Seed Round 04-May-2006 Completed Generating Revenue
To view Parsortix’s complete valuation and funding history, request access »

Parsortix Patents

Parsortix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2850892-A1 Removal of particulates from blood using an apparatus including a size-differentiating element Inactive 09-Apr-2014 0000000000
AU-2015234366-A1 Removal of particulates from blood using an apparatus including a size-differentiating element Inactive 09-Apr-2014 000000000000
AU-2014202043-A1 Removal of particulates from blood using an apparatus including a size-differentiating element Inactive 09-Apr-2014 00000000 0
US-20150290368-A1 Removal of particulates from blood using an apparatus including a size-differentiating element Inactive 09-Apr-2014 0000000000 0
EP-2930513-A1 Removal of particulates from blood using an apparatus including a size-differentiating element Inactive 09-Apr-2014 G01N33/491 0
To view Parsortix’s complete patent history, request access »

Parsortix Executive Team (2)

Name Title Board Seat Contact Info
Shane Booth Ph.D Chief Executive & President
George Hvichia Co-Founder & Chief Technology Officer
To view Parsortix’s complete executive team members history, request access »

Parsortix Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ANGLE Technology Ventures Corporate Venture Capital Minority 000 0000 000000 0
Ben Franklin Technology Partners of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
Science Center Accelerator/Incubator Minority 000 0000 000000 0
To view Parsortix’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »